Skip to main content Skip to search Skip to main navigation
News: Artificial Intelligence

EMA: Guiding Principles on LLMs, a Category of Generative AI

On 5 September 2024 the EMA and the Heads of Medicine Agencies HMA, published guiding principles that set how EU medicine regulators can use large language models (LLMs), a form of generative AI, focusing on text generation in regulatory science and for regulatory activities. The 10-page document provides high-level recommendations to facilitate LLMs' safe, responsible, and effective use, being of interest to anyone who uses or would like to use such AI models in the future.

"LLMs have enormous transformative potential," says EMA, “but also present challenges: variability in results, returning of irrelevant or inaccurate responses (so-called hallucinations), and potential data security risks." On the other hand, LLMs could be applied to query the extensive documentation regulators receive, to automate knowledge/data mining processes, or as virtual AI assistants in everyday administrative tasks.

Therefore, the document aims to build an understanding of the capabilities and limitations of these applications among staff at regulatory agencies across the EU to harness the potential of LLMs effectively and avoid pitfalls and risks. General ethical considerations, e.g. the rule of law, accountability, security, safety, transparency, non-discrimination, misinformation harms, and malicious uses or copyright issues are included.

Being part of the multiannual AI work plan to 2028 set out by EMA, the guiding principles are considered a living document that will be regularly updated. An EMA factsheet on LLMs can be found here.


Source:

EMA: Guiding principles on the use of LLMs in regulatory science and for medicines regulatory activities

EMA: Factsheet on the 4 principles for safe and responsible use of LLMs

 

Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The demo access is non-binding and ends automatically.

Test it now for free

You may also be interested in the following articles:

News: EMA

EMA Clarifies Batch Numbering for Parallel-Traded Medicines

EMA updated its GMP/GDP Q&A collection by revising the answer to Question 4 concerning Chapter 5 of the EU GMP Guide. It explains which batch numbers should appear on the packaging of parallel-traded medicines.

Read more
Question of the Week | GMP-Verlag

Why is it Important to use Consistent Microbiological Air Monitoring Methods in Pharmaceutical Cleanrooms?

Here's the answer:
Read more
Cleaning Validation: When PDE Reports and the Worst-Case Selection do not Align

Cleaning Validation: When PDE Reports and the Worst-Case Selection do not Align

Robust PDE reports form the basis of risk-based cleaning validation. This article highlights common deficiencies identified during GMP inspections and explains how they can be avoided.

Read more
News: Europe

EDQM: New Working Party on 3D-printed Medicinal Products

The European Pharmacopoeia Commission (EPC) approved the creation of a working party on 3D-printed medicinal products. Its aim is to support the development of appropriate quality standards in the European Pharmacopoeia (Ph. Eur.).
Read more
EMA: 14 New Nitrosamines for Appendix 1

EMA: 14 New Nitrosamines for Appendix 1

Appendix 1 of EMA’s Questions and Answers on nitrosamine impurities has been updated. This appendix contains acceptable intakes (AIs) established for N-nitrosamines.
Read more
WHO: Draft Revision of its Guidelines on Quality Risk Management

WHO: Draft Revision of its Guidelines on Quality Risk Management

WHO published a revised draft of its “WHO guidelines on quality risk management”. Working document QAS/26.994 is open for public comment until 15 November 2026.
Read more
Previous
Next